Compare IPST & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPST | SHPH |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.9M |
| IPO Year | N/A | 2022 |
| Metric | IPST | SHPH |
|---|---|---|
| Price | $2.45 | $2.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $164.00 | N/A |
| AVG Volume (30 Days) | 22.2K | ★ 1.0M |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.16 | N/A |
| Revenue Next Year | $60.33 | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.38 |
| 52 Week High | $15.08 | $6.15 |
| Indicator | IPST | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 52.08 |
| Support Level | $0.43 | $1.40 |
| Resistance Level | $3.95 | $3.56 |
| Average True Range (ATR) | 0.30 | 0.58 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 27.03 | 3.38 |
IP Strategy Holdings Inc operate a diversified business centered on digital asset-based infrastructure and intellectual property (IP) management, supplemented by a legacy craft spirits operating segment. The Company provides public market investors with broad exposure to the around $80 trillion programmable intellectual property economy in a regulated equity format. Its treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.